Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Breast Cancer Research and Treatment
|
October 30, 2024
Molecular tumor board in patients with metastatic breast cancer
Luca Boscolo Bielo, Elena Guerini Rocco, Edoardo Crimini, et al.
The Oncologist
|
September 16, 2023
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
Luca Mazzarella, Federica Giugliano, Eleonora Nicolo, et al.
Cancers
|
January 8, 2025
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
Angela Esposito, Edoardo Crimini, Carmen Criscitiello, et al.
JCO Precision Oncology
|
November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Malini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
British Journal of Cancer
|
June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, et al.
NPJ Breast Cancer
|
July 10, 2025
Genomic landscape of breast cancer in elderly patients
Pier Selenica, Higinio Dopeso, Matteo Repetto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical and Translational Medicine
|
May 29, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors
Yonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2026
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors
Matteo Repetto, Allison L Richards, Monica F Chen, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Breast Cancer Research and Treatment
|
October 30, 2024
Molecular tumor board in patients with metastatic breast cancer
Luca Boscolo Bielo, Elena Guerini Rocco, Edoardo Crimini, et al.
The Oncologist
|
September 16, 2023
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
Luca Mazzarella, Federica Giugliano, Eleonora Nicolo, et al.
Cancers
|
January 8, 2025
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
Angela Esposito, Edoardo Crimini, Carmen Criscitiello, et al.
JCO Precision Oncology
|
November 16, 2023
Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Malini M Gandhi, Biagio Ricciuti, Guilherme Harada, et al.
British Journal of Cancer
|
June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, et al.
NPJ Breast Cancer
|
July 10, 2025
Genomic landscape of breast cancer in elderly patients
Pier Selenica, Higinio Dopeso, Matteo Repetto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical and Translational Medicine
|
May 29, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors
Yonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2026
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors
Matteo Repetto, Allison L Richards, Monica F Chen, et al.
Page
of 5